BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 16053033)

  • 1. Triple-modality therapy for a woman with locally advanced thoracic esophageal adenocarcinoma, Part 2.
    Schefter TE; Patel M; McCarter M; Kane M; Russ PD; Nash SR; Shah RJ; Mitchell JD
    Oncology (Williston Park); 2005 Jun; 19(7):830, 835-6, 838 passim. PubMed ID: 16053033
    [No Abstract]   [Full Text] [Related]  

  • 2. Triple-modality therapy for a woman with locally advanced thoracic esophageal adenocarcinoma, part 1.
    Schefter TE; Patel M; McCarter M; Kane M; Russ PD; Nash SR; Shah RJ; Mitchell JD
    Oncology (Williston Park); 2005 May; 19(6):775-8, 783-4, 788 passim. PubMed ID: 15971452
    [No Abstract]   [Full Text] [Related]  

  • 3. For localized gastroesophageal cancer, you give chemoradiation before surgery, but then what happens?
    Ajani JA; Correa AM; Swisher SG; Wu TT
    J Clin Oncol; 2007 Sep; 25(27):4315-6. PubMed ID: 17878485
    [No Abstract]   [Full Text] [Related]  

  • 4. Who profits from neoadjuvant radiochemotherapy for locally advanced esophageal carcinoma?
    Elsaleh H; Farrell JJ; Crane CH
    J Gastroenterol Hepatol; 2009 May; 24(5):708-10. PubMed ID: 19646012
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
    Pennathur A; Luketich JD; Landreneau RJ; Ward J; Christie NA; Gibson MK; Schuchert M; Cooper K; Land SR; Belani CP
    Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Perioperative therapy in esophageal and stomach carcinoma].
    Stahl M; Wilke H; Meyer HJ
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():85-92. PubMed ID: 8692126
    [No Abstract]   [Full Text] [Related]  

  • 7. Complications of multimodality therapy.
    Putnam JB
    Chest Surg Clin N Am; 1998 Aug; 8(3):663-80, x. PubMed ID: 9742342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical utility of postchemoradiation endoscopic brush cytology and biopsy in predicting residual esophageal adenocarcinoma.
    Peng HQ; Halsey K; Sun CC; Manucha V; Nugent S; Rodgers WH; Suntharalingam M; Greenwald BD
    Cancer; 2009 Dec; 117(6):463-72. PubMed ID: 19806643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The multidisciplinary management of gastrointestinal cancer. Multimodal treatment of oesophageal cancer.
    Veuillez V; Rougier P; Seitz JF
    Best Pract Res Clin Gastroenterol; 2007; 21(6):947-63. PubMed ID: 18070697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status of multimodality therapy for esophageal carcinoma.
    Tak VM; Naunheim KS
    J Surg Res; 2004 Mar; 117(1):22-9. PubMed ID: 15013710
    [No Abstract]   [Full Text] [Related]  

  • 11. [Understanding and controversy of the gastroesophageal junction adenocarcinoma].
    Zhang XH; Wang QZ
    Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):947-9. PubMed ID: 19174001
    [No Abstract]   [Full Text] [Related]  

  • 12. Reduced incidence of nodal micrometastasis after major response to neoadjuvant chemoradiation in locally advanced esophageal cancer.
    Prenzel KL; König A; Schneider PM; Schnickmann C; Baldus SE; Schröder W; Bollschweiler E; Dienes HP; Mueller RP; Izbicki JR; Hölscher AH
    Ann Surg Oncol; 2007 Feb; 14(2):954-9. PubMed ID: 17103071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of esophageal cancer based on histology: a surveillance epidemiology and end results analysis.
    Chang DT; Chapman C; Shen J; Su Z; Koong AC
    Am J Clin Oncol; 2009 Aug; 32(4):405-10. PubMed ID: 19415029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response.
    Barbour AP; Jones M; Gonen M; Gotley DC; Thomas J; Thomson DB; Burmeister B; Smithers BM
    Ann Surg Oncol; 2008 Oct; 15(10):2894-902. PubMed ID: 18663531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: prognostic value of circumferential resection margin and stratification of N1 category.
    Saha AK; Sutton C; Rotimi O; Dexter S; Sue-Ling H; Sarela AI
    Ann Surg Oncol; 2009 May; 16(5):1364-70. PubMed ID: 19252949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of neoadjuvant therapy for esophageal adenocarcinoma.
    Ku GY; Ilson DH
    Surg Oncol Clin N Am; 2009 Jul; 18(3):533-46. PubMed ID: 19500742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical analysis of 108 cases with adenocarcinoma Barretts's esophagus].
    Han JQ; Liu Q; Liang RX; Qu FS; Yan TX; Sun YH; Li XQ
    Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):470-3. PubMed ID: 17974287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invited commentary.
    Hoover EL
    Ann Thorac Surg; 2007 Apr; 83(4):1278. PubMed ID: 17383326
    [No Abstract]   [Full Text] [Related]  

  • 19. American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma.
    Rizk NP; Venkatraman E; Bains MS; Park B; Flores R; Tang L; Ilson DH; Minsky BD; Rusch VW;
    J Clin Oncol; 2007 Feb; 25(5):507-12. PubMed ID: 17290058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemoradiation versus chemotherapy for patients undergoing esophagectomy for esophageal cancer.
    Luu TD; Gaur P; Force SD; Staley CA; Mansour KA; Miller JI; Miller DL
    Ann Thorac Surg; 2008 Apr; 85(4):1217-23; discussion 1223-4. PubMed ID: 18355499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.